Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial.
Balinda HU, Kelly WJ, Kaklamani VG, Lathrop KI, Canola MM, Ghamasaee P, Sareddy GR, Michalek J, Gilbert AR, Surapaneni P, Tiziani S, Pandey R, Chiou J, Lodi A, Floyd JR 2nd, Brenner AJ. Balinda HU, et al. Among authors: sareddy gr. Nat Commun. 2024 Aug 7;15(1):6707. doi: 10.1038/s41467-024-50558-9. Nat Commun. 2024. PMID: 39112464 Free PMC article.
Preclinical Development of Brain Permeable ERβ Agonist for the Treatment of Glioblastoma.
Pratap UP, Tidwell M, Balinda HU, Clanton NA, Yang X, Viswanadhapalli S, Sareddy GR, Liang D, Xie H, Chen Y, Lai Z, Tekmal RR, McHardy SF, Brenner AJ, Vadlamudi RK. Pratap UP, et al. Among authors: sareddy gr. Mol Cancer Ther. 2023 Nov 1;22(11):1248-1260. doi: 10.1158/1535-7163.MCT-23-0031. Mol Cancer Ther. 2023. PMID: 37493258 Free PMC article.
FASN inhibition as a potential treatment for endocrine-resistant breast cancer.
Gruslova A, McClellan B, Balinda HU, Viswanadhapalli S, Alers V, Sareddy GR, Huang T, Garcia M, deGraffenried L, Vadlamudi RK, Brenner AJ. Gruslova A, et al. Among authors: sareddy gr. Breast Cancer Res Treat. 2021 Jun;187(2):375-386. doi: 10.1007/s10549-021-06231-6. Epub 2021 Apr 24. Breast Cancer Res Treat. 2021. PMID: 33893909
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
Li M, Viswanadhapalli S, Santhamma B, Pratap UP, Luo Y, Liu J, Altwegg KA, Tang W, Liu Z, Li X, Ebrahimi B, Yan H, Zou Y, Konda S, Sareddy GR, Xu Z, Chen Y, Rao MK, Brenner AJ, Kaklamani VG, Tekmal RR, Ahmed G, Raj GV, Nickisch KJ, Nair HB, Vadlamudi RK. Li M, et al. Among authors: sareddy gr. Commun Biol. 2021 Oct 29;4(1):1235. doi: 10.1038/s42003-021-02741-7. Commun Biol. 2021. PMID: 34716410 Free PMC article.
PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling.
Sareddy GR, Pratap UP, Viswanadhapalli S, Venkata PP, Nair BC, Krishnan SR, Zheng S, Gilbert AR, Brenner AJ, Brann DW, Vadlamudi RK. Sareddy GR, et al. Neurooncol Adv. 2019 May-Dec;1(1):vdz042. doi: 10.1093/noajnl/vdz042. Epub 2019 Nov 5. Neurooncol Adv. 2019. PMID: 32309805 Free PMC article.
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Alejo S, Palacios BE, Venkata PP, He Y, Li W, Johnson JD, Chen Y, Jayamohan S, Pratap UP, Clarke K, Zou Y, Lv Y, Weldon K, Viswanadhapalli S, Lai Z, Ye Z, Chen Y, Gilbert AR, Suzuki T, Tekmal RR, Zhao W, Zheng S, Vadlamudi RK, Brenner AJ, Sareddy GR. Alejo S, et al. Among authors: sareddy gr. Neuro Oncol. 2023 Jul 6;25(7):1249-1261. doi: 10.1093/neuonc/noad018. Neuro Oncol. 2023. PMID: 36652263 Free PMC article.
KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Zhou M, Venkata PP, Viswanadhapalli S, Palacios B, Alejo S, Chen Y, He Y, Pratap UP, Liu J, Zou Y, Lai Z, Suzuki T, Brenner AJ, Tekmal RR, Vadlamudi RK, Sareddy GR. Zhou M, et al. Among authors: sareddy gr. Breast Cancer Res Treat. 2021 Jan;185(2):343-357. doi: 10.1007/s10549-020-05963-1. Epub 2020 Oct 14. Breast Cancer Res Treat. 2021. PMID: 33057995
KDM1 is a novel therapeutic target for the treatment of gliomas.
Sareddy GR, Nair BC, Krishnan SK, Gonugunta VK, Zhang QG, Suzuki T, Miyata N, Brenner AJ, Brann DW, Vadlamudi RK. Sareddy GR, et al. Oncotarget. 2013 Jan;4(1):18-28. doi: 10.18632/oncotarget.725. Oncotarget. 2013. PMID: 23248157 Free PMC article.
69 results